Aileron Therapeutics Inc (ALRN)

NASDAQ
1.0300
-0.0100(-0.96%)
After Hours
1.0300
0.0000(0.00%)
- Real-time Data
  • Volume:
    136,479
  • Bid/Ask:
    1.0300/1.0900
  • Day's Range:
    1.0200 - 1.0500

ALRN Overview

Prev. Close
1.04
Day's Range
1.02-1.05
Revenue
-
Open
1.02
52 wk Range
0.8811-2.45
EPS
-0.47
Volume
136,479
Market Cap
93.04M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
506,456
P/E Ratio
-
Beta
2.72
1-Year Change
17.05%
Shares Outstanding
90,327,848
Next Earnings Date
Aug 10, 2021
What is your sentiment on Aileron Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Aileron Therapeutics Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsSellBuySellStrong SellStrong Sell
SummaryStrong SellNeutralStrong SellStrong SellStrong Sell

Aileron Therapeutics Inc Company Profile

Aileron Therapeutics Inc Company Profile

Employees
8

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Read More
  • ALRN-6924 is one of the most advanced late cancer treatments that can possibly save millions of lives. Do some research and you'll understand why this stock is critically undervalued atm.
    0
    • cheap right now. Just bought 2000 shares. Would be a even more terrific entry price at 1.8, although unlikely to see such a low price.
      0
      • no signal says buy at 1.8 just yet, still need to wait.
        0
    • Mid February results released.. It will be huge jump for ALRN.. I think this is the last opportunity to buy cheap within these two days.. Good luck guys.. I hope you got more than that..
      0
      • couldn't say it better, strong buy and hold for this company. Will probably add more shares today. It will skyrocket once results are positive as the matters of research are truly significant. Its leade candidate targets tumor proteins for the treatment of a range of cancers. Aileron is also currently collaborating with Pfizer.
        0
    • one of the last chances to add a dip imo🚀🚀
      0
      • Quickly loading up more
        0
    • TNXP.. ATHX.. ALRN.. Working on Cancer reserch and they are very close to give great results within weeks.. Investors collecting them.. Be the first to collect there shares.. Not the last.. Good luck guys..
      0
      • Target price for some analysts above 15$.. Buy and hold guys..
        0
        • Which analysts?
          0
        • Simone Bertola You can check the street target almost from all finance websites, yahoo finance, or marketwatch. The target is at 4 to 5. 15 sounds like a fraud
          0
      • its takeoff season🚀 specifically for a company that is Cancer research based with a strong volume.
        0
        • Baiden said we need too invest more in Medicine and Drogs to avoid any thing like Covid.. Be ready guys for wave of increase for Medicine and research Stocks like this stock.. Good luck guys..
          0
          • The volume is decente, just keep it for a natural grow.
            0
            • this will skyrocket once it passes 2.22 for good🚀🚀
              0
              • Saw on Tip Ranks average price target $4 and a high $5
                0
                • https://www.markets.co/jonestrading-sticks-to-their-buy-rating-for-aileron-therapeutics-alrn/287884/?
                  0
                  • If we go upper resistance 2 ****then will fly to 5$..be ready guys..
                    0
                    • First target 5$ then 10$ then 15$.. Just buy and hold.. Great future.. Good luck guys..
                      0
                      • Never sell.. It is for a year will be 20$ or more..
                        0
                        • ALRN making a cup with handle.. Be ready to fly soon.. Maybe today or tomorrow.. Good luck guys..
                          0
                          • Today is the day.. Be ready.. Good luck guys..
                            0
                            • New fundamental investors, including Acorn Bioventures, BVF Partners, L.P., Maven Investment Partners and Grand Oaks Capital, participated in the offering of 32,630,983 of its shares of common stock at a purchase price of $1.10 per share, for gross proceeds of $35.9 million. This will enable it to fund its current strategic plan into the second half of 2023, including the planned clinical trial of ALRN-6924 in patients with advanced non-small cell lung cancer (NSCLC).
                              0
                              • insider buys 9million shares
                                0
                                • after hours +28%??? I cant find any news? greenfee, Bert (Netherlands)
                                  0
                                  • insiders buying
                                    0
                                • what is the reason for ++++
                                  0
                                  • go back 6$
                                    0
                                    • I am done with this *******
                                      1
                                      • buy
                                        0
                                    • Target?
                                      0
                                      • €24!!!!
                                        0
                                      • 12 USD 2021
                                        0
                                    • ALRN Aileron Therapeutics Rickenbach Josef H Von Director Buy 227,272 shares @ $1.10 $249,999.20 6/8/2020 $1.29
                                      1
                                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.